Retrospective Cohort Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Feb 24, 2017; 7(1): 34-42
Published online Feb 24, 2017. doi: 10.5500/wjt.v7.i1.34
Risk factors and outcomes of delayed graft function in renal transplant recipients receiving a steroid sparing immunosuppression protocol
Michelle Willicombe, Anna Rizzello, Dawn Goodall, Vassilios Papalois, Adam G McLean, David Taube
Michelle Willicombe, Anna Rizzello, Dawn Goodall, Vassilios Papalois, Adam G McLean, David Taube, Imperial College Kidney and Transplant Centre, Hammersmith Hospital, London W12 0HS, United Kingdom
Author contributions: All the authors contributed to the manuscript.
Institutional review board statement: This study was approved by the Imperial College Renal and Transplant Centre, Transplant Clinical and Research Group.
Informed consent statement: No individual informed consent was required for this study.
Conflict-of-interest statement: The authors declare no conflicts of interest regarding this manuscript.
Data sharing statement: No data were created no data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Michelle Willicombe, MA, MRCP, MD, Imperial College Kidney and Transplant Centre, Hammersmith Hospital, South Wharf Road, London W12 0HS, United Kingdom. michelle.willicombe@imperial.nhs.uk
Telephone: +44-020-33135165 Fax: +44-020-33135169
Received: August 8, 2016
Peer-review started: August 10, 2016
First decision: September 12, 2016
Revised: October 27, 2016
Accepted: December 7, 2016
Article in press: December 9, 2016
Published online: February 24, 2017
Processing time: 198 Days and 12.6 Hours
Core Tip

Core tip: Alemtuzumab induction may help mitigate the early rejection risk associated with delayed graft function following renal transplantation. This may help with the management of recipients of transplants at high risk of delayed graft function, as it may lessen the need for repeated histological sampling.